NAPRx CNPR Exam Questions and ANSWERs 100% Verified | Guaranteed Pass A+

1. What is the primary purpose of the "Orange Book" published by the FDA? A. To list average wholesale prices of drugs B. To provide prescribing information for physicians *C. To identify drug products approved as safe and effective* D. To catalog medicinal herbs and supplements ANSWER: C 2. The "Purple Book" is an FDA reference that lists biological products, including their biosimilar and interchangeable products. What is its official title? A. Database of Biologic Efficacy and Safety B. Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations C. Compendium of Biologics and Biosimilars D. Guide to Therapeutic Equivalence ANSWER: B 3. In pharmaceutical sales, what does the acronym "PDMA" stand for? A. Prescription Drug Marketing Act B. Pharmaceutical Distribution and Management Association C. Physician Drug Monitoring Agency D. Proprietary Drug Manufacturing Act ANSWER: A 4. A drug that has the potential for abuse and dependence, such as oxycodone, is classified by the DEA as a: A. Schedule II controlled substance B. Schedule III controlled substance C. Schedule I controlled substance D. Prescription-only drug ANSWER: A 5. What is the main objective of a pharmaceutical sales representative's "detail"? A. To take a drug order from the physician B. To provide comprehensive information about a product to a healthcare professional C. To set up the office's pharmaceutical inventory D. To discuss patient billing with the office manager ANSWER: B 6. The "Fair Balance" in promotional materials refers to: A. Equal time spent on all products in a portfolio B. A fair and balanced presentation of a drug's risks and benefits C. A pricing strategy that is fair to all purchasers D. The equitable distribution of samples ANSWER: B 7. Off-label promotion of a prescription drug is: A. Encouraged if supported by strong scientific evidence B. Illegal and a violation of the Food, Drug, and Cosmetic Act C. Permitted for drugs that are over five years old D. Allowed if only done verbally and not in writing ANSWER: B 8. The FDA's MedWatch program is primarily designed for: A. Tracking physician prescribing habits B. Reporting adverse events and product problems C. Monitoring drug sales data D. Providing medication guides to patients ANSWER: B 9. What is the primary role of an Institutional Review Board (IRB)? A. To review the financial costs of clinical trials B. To manufacture and package clinical trial supplies C. To protect the rights and welfare of human research subjects D. To analyze the clinical data from a research study ANSWER: C 10. A drug's "Indications" are: A. The side effects a patient may experience B. The diseases or conditions for which the drug is approved to be used C. The chemical structure of the active ingredient D. The contraindications for use ANSWER: B 11. The "Half-life" of a drug is best defined as the time required for: A. The drug to be completely eliminated from the body B. The plasma concentration of the drug to be reduced by 50% C. The drug to be absorbed into the bloodstream D. The drug to achieve its maximum therapeutic effect ANSWER: B 12. The first phase of clinical testing (Phase I) primarily focuses on: A. Establishing the drug's efficacy in a large patient population B. Determining the safety and pharmacokinetics in a small number of healthy volunteers C. Conducting post-marketing surveillance D. Testing the drug against an active comparator in patients ANSWER: B 13. Bioavailability refers to: A. The rate and extent to which the active drug is absorbed and becomes available at the site of action B. The biological origin of a drug's active ingredient C. The ability of a drug to be dissolved in water D. The stability of a drug in a biological fluid ANSWER: A 14. What type of drug name is "atorvastatin calcium"? A. Brand Name B. Generic Name C. Chemical Name D. Proprietary Name ANSWER: B 15. The "Placebo Effect" is: A. A harmful reaction to an inactive substance B. A therapeutic effect produced by an inactive substance due to the patient's belief in the treatment C. The expected side effect profile of a drug D. The effect of a drug on a control group in a study ANSWER: B 16. A "Black Box Warning" is: A. A warning on the shipping container for hazardous drugs B. The strongest safety warning the FDA can mandate for a prescription drug C. A warning for drugs that are over-the-counter D. An internal warning for pharmacy staff only ANSWER: B 17. The primary federal law governing the adulteration and misbranding of foods, drugs, and cosmetics is the: A. Prescription Drug Marketing Act (PDMA) B. Food, Drug, and Cosmetic Act (FD&C Act) C. Health Insurance Portability and Accountability Act (HIPAA) D. Controlled Substances Act (CSA) ANSWER: B 18. What does the term "Formulary" refer to in a hospital or health plan? A. The list of preferred drugs approved for use and reimbursement B. The chemical formula of a drug C. The physical form of a drug (tablet, capsule, etc.) D. The documentation required for prior authorization ANSWER: A 19. A "Contraindication" is: A. A common side effect B. A situation in which a drug should not be used because it may be harmful C. An indication for off-label use D. A warning about drug-food interactions ANSWER: B 20. The process of a drug moving from the site of administration into the bloodstream is known as: A. Distribution B. Metabolism C. Absorption D. Excretion ANSWER: C 21. Which entity is responsible for enforcing the laws and regulations governing controlled substances? A. Food and Drug Administration (FDA) B. Drug Enforcement Administration (DEA) C. Department of Health and Human Services (HHS) D. Federal Trade Commission (FTC) ANSWER: B 22. The "Therapeutic Index" of a drug is a ratio that compares: A. The cost of the drug to its therapeutic benefit B. The lethal dose to the effective dose C. The brand name price to the generic price D. The absorption rate to the excretion rate ANSWER: B 23. What is the main goal of Phase III clinical trials? A. To assess pharmacokinetics in healthy volunteers B. To monitor long-term safety after market approval C. To confirm efficacy, monitor side effects, and compare to standard treatments in a large patient group D. To conduct initial safety testing in a small patient population ANSWER: C 24. A "Me-too" drug is best described as: A. A generic copy of a brand-name drug B. A drug that is structurally very similar to an existing drug, with only minor differences C. A drug that is the first in its class to treat a condition D. A drug that is used in combination therapy ANSWER: B 25. Pharmacodynamics is the study of: A. The movement of drugs through the body B. The biochemical and physiological effects of drugs and their mechanisms of action C. The economic aspects of drug utilization D. The genetic factors influencing drug response ANSWER: B 26. Which of the following is NOT a typical component of a pharmaceutical sales call? A. Detailing the product's features and benefits B. Handling objections C. Asking for the business (e.g., a script) D. Taking a physical inventory of the doctor's sample closet ANSWER: D 27. The "First-Pass Effect" refers to: A. The first time a patient takes a medication B. The metabolism of a drug in the liver before it reaches systemic circulation C. The initial absorption of a drug in the stomach D. The first round of clinical testing in humans ANSWER: B 28. What is an "Adverse Drug Reaction" (ADR)? A. A harmful and unintended response to a drug B. An expected side effect listed in the prescribing information C. A drug interaction that reduces efficacy D. An allergic reaction to a drug's inactive ingredients ANSWER: A 29. The "Orange Book" assigns therapeutic equivalence codes. What does an "AB" rating signify? A. The drug is not therapeutically equivalent to the reference drug. B. The drug is therapeutically equivalent to the reference drug. C. The drug has unresolved bioequivalence issues. D. The drug is a controlled substance. ANSWER: B 30. A "Warning Letter" from the FDA is: A. A public notice of a drug recall B. An informal communication with no legal standing C. A formal communication that notifies a company of violations found during an inspection D. A letter sent to physicians warning them about a drug's side effects ANSWER: C